Table 1.
Baseline and clinical characteristics of 118 severe COPD patients attended for COPD exacerbation (ECOPD), with and without P. aeruginosa isolation
| Whole group | PA-group | Non PA-group | P value | |
|---|---|---|---|---|
|
Subjects, (%) |
118 |
41 (34.7) |
77 (65,3) |
… |
|
Follow-up (days), m (SD) |
1003±306 |
1036.9±347.5 |
984.9±282.3 |
0.41 |
|
Age (years), m (SD) |
69.5±8.2 |
70.3±7.7 |
69±8.5 |
0.42 |
|
Current smoking, (%) |
13 (11) |
2 (4.9) |
11 (14.3) |
0.21 |
|
Pack-year, m (SD) |
63.3±31,9 |
69.4±36.3 |
60±28.9 |
0.15 |
|
Alcohol abuse >80 g/l, n (%) |
3 (2.5) |
1 (2.4) |
2 (2.6) |
1 |
|
Influenza vaccination, n (%) |
105 (89) |
38 (92.7) |
67 (87) |
0.53 |
|
Pneumococcus vaccination n (%) |
57 (48.3) |
23 (56.1) |
34 (44.2) |
0.21 |
|
Body mass index (Kgr/m
2
) |
27.5±4.6 |
26.5±4 |
28.1±4.9 |
0.17 |
|
FEV1 post-BD, (L), m (SD) |
0.97±0.3 |
0.91±0.28 |
1.0±0.31 |
0.13 |
|
FEV1 post-BD, (% predicted), m (SD) |
34±11 |
34±13 |
34.3±10 |
0.82 |
|
GOLD stage IV, n (%) |
71 (60) |
27 (66) |
44 (57) |
0.35 |
|
BODE score, m (SD) |
5.1±1,6 |
5.3±1,5 |
5±1.6 |
0.38 |
|
Home oxygen therapy, n (%) |
50 (42.4) |
21 (51.2) |
29 (37.7) |
0.15 |
|
Charlson, m (SD) |
4.13±1.5 |
4.29±1.5 |
4.04±1.5 |
0.39 |
|
Bronchiectasis score, m (SD) |
2.1±2,6 |
3±3.5 |
1.6±1.8 |
0.02 |
|
ECOPD during follow-up, m (SD) |
3.19±2.9 |
4.4±4 |
2.5±2 |
0.008 |
|
ECOPD/year, m (SD) |
2.19±2 |
3±2.7 |
1.7±1.4 |
0.006 |
|
Antibiotic prescriptions* |
8.9±7.5 |
12.5±9.2 |
7.01±5.7 |
<0.001 |
|
Antibiotic prescriptions/year |
3.3±2.5 |
4.7±2.9 |
2.6±1.8 |
<0.001 |
|
Corticosteroid courses* |
6.3±5.8 |
8±6.3 |
5.5±5.4 |
0.02 |
|
Corticosteroid courses/year |
2.30±1.8 |
2.9±2 |
1.9±1.6 |
0.004 |
|
Days of hospital stay* |
29.4±37.9 |
43.8±43.9 |
21.3±31.9 |
0.005 |
| Mortality, n (%) | 17 (14.4) | 11 (27) | 6 (8) | 0.005 |
Data are presented as means±SD or n (%), unless otherwise stated. PA group=P. aeruginosa group; Non PA group=Non P. aeruginosa group; ns=not significant; post-BD=post bronchodilator. *prior year included.